Clinical Trials for Breast Cancer

A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 Mutations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients have metastatic or unresectable ERα-positive, HER2-negative breast cancer with ESR1 mutations and prior progression on endocrine therapy; participants receive escalating doses of oral tamoxifen, a selective estrogen receptor modulator, with FES-PET/CT imaging used to evaluate ER blockade and optimize tamoxifen dosing for this population.

ClinicalTrials.gov ID: NCT04174352

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with locally advanced, unresectable, or metastatic HER2-expressing solid tumors (excluding breast, gastric, and colorectal), including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare tumors, who have progressed after prior therapy or lack alternative options. All patients receive trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor to HER2-expressing tumor cells.

ClinicalTrials.gov ID: NCT04482309

Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed/Refractory Locally Advanced or Metastatic NY-ESO-1-Expressing Triple Negative Breast Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adult women with HLA-A2-positive, relapsed or refractory advanced or metastatic triple negative breast cancer that overexpresses NY-ESO-1. Participants receive autologous T cells genetically engineered to express a T-cell receptor targeting HLA-A2/NY-ESO-1 (A2-ESO-1 TCR-T cells) after lymphodepletion, followed by low-dose IL-2 to support T cell activity.

ClinicalTrials.gov ID: NCT05989828

AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Eligible patients are adults with unresectable or metastatic solid tumors harboring the AKT1 E17K mutation who have not previously received PI3K or mTOR inhibitors and have good performance status. The study tests ALTA2618, an oral, mutation-selective covalent allosteric inhibitor of AKT1 E17K.

ClinicalTrials.gov ID: NCT06533059

A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Adults with hormone receptor-positive, HER2-negative metastatic breast cancer—particularly those with progressive bone metastases after prior endocrine therapy (including CDK4/6 inhibitors) and ≤1 prior chemotherapy for metastatic disease—are eligible for a randomized trial comparing capecitabine plus standard anti-resorptive therapy to capecitabine plus zunsemetinib, an oral MK2 inhibitor targeting pro-inflammatory cytokine signaling.

ClinicalTrials.gov ID: NCT06374459

Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial enrolls adults with metastatic or unresectable HER-2 or EGFR-expressing breast or GI cancers who have progressed after or refused standard therapy, including those with stable brain metastases. Patients receive two chimeric HER-2 B cell peptide vaccines designed to stimulate a strong humoral immune response against HER-2-expressing tumors.

ClinicalTrials.gov ID: NCT06414733

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls patients aged 70 and older with hormone receptor positive, HER2 negative metastatic breast cancer who have progressed on prior endocrine therapy and a CDK4/6 inhibitor, treating them with abemaciclib (a selective CDK4/6 inhibitor) plus endocrine therapy to assess tolerability and safety in this older population.

ClinicalTrials.gov ID: NCT04305834

I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients are those with metastatic, triple-negative, HER2-negative breast cancer who are circulating tumor cell (CTC) positive and have not received prior chemotherapy for metastatic disease but were previously treated with anthracyclines and taxanes. Treatment consists of pembrolizumab, a PD-1 immune checkpoint inhibitor, combined with carboplatin starting at cycle 3.

ClinicalTrials.gov ID: NCT03213041

Phase II Trial Of Fulvestrant Plus Abemaciclib In Er-Positive, Her2-Negative Metastatic Breast Cancer Immediately After Failure Of A Cdk4/6 Inhibitor

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with ER-positive, HER2-negative metastatic breast cancer who have progressed on prior CDK4/6 inhibitor plus aromatase inhibitor therapy, treating them with a 1-month fulvestrant monotherapy lead-in followed by fulvestrant combined with abemaciclib, a selective CDK4/6 inhibitor. Eligible patients must have measurable or bone-only disease and good performance status.

ClinicalTrials.gov ID: NCT05305924

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with previously treated, castration-sensitive oligometastatic prostate adenocarcinoma (1-5 PET-detected bone or nodal/soft tissue metastases, including at least one extrapelvic), randomizing them to stereotactic ablative body radiation therapy (SABR) plus either relugolix (an oral GnRH receptor antagonist) or placebo for 6 months.

ClinicalTrials.gov ID: NCT05053152